发明公开
- 专利标题: SUBSTITUTED NICOTINAMIDE COMPOUNDS
- 专利标题(中): 取代烟酰胺
-
申请号: EP06826996.8申请日: 2006-10-30
-
公开(公告)号: EP1945028A2公开(公告)日: 2008-07-23
- 发明人: HAMBLETT, Christopher , MAMPREIAN, Dawn, M. , METHOT, Joey, L. , MILLER, Thomas , SLOMAN, David, L. , STANTON, Matthew, G. , WILSON, Kevin
- 申请人: Merck & Co., Inc.
- 申请人地址: 126 East Lincoln Avenue Rahway, NJ 07065-0907 US
- 专利权人: Merck & Co., Inc.
- 当前专利权人: Merck & Co., Inc.
- 当前专利权人地址: 126 East Lincoln Avenue Rahway, NJ 07065-0907 US
- 代理机构: Hussain, Deeba
- 优先权: US732932P 20051103
- 国际公布: WO2007055942 20070518
- 主分类号: A01N43/40
- IPC分类号: A01N43/40 ; A61K31/44
摘要:
The present invention relates to a novel class of substituted nicotinamides.. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
信息查询
IPC分类: